Logo image of LPTX

LEAP THERAPEUTICS INC (LPTX) Stock Fundamental Analysis

NASDAQ:LPTX - Nasdaq - US52187K2006 - Common Stock - Currency: USD

0.4633  0 (-0.04%)

Premarket: 0.4633 0 (0%)

Fundamental Rating

2

Overall LPTX gets a fundamental rating of 2 out of 10. We evaluated LPTX against 571 industry peers in the Biotechnology industry. While LPTX seems to be doing ok healthwise, there are quite some concerns on its profitability. LPTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year LPTX has reported negative net income.
In the past year LPTX has reported a negative cash flow from operations.
In the past 5 years LPTX always reported negative net income.
In the past 5 years LPTX always reported negative operating cash flow.
LPTX Yearly Net Income VS EBIT VS OCF VS FCFLPTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

LPTX's Return On Assets of -99.66% is on the low side compared to the rest of the industry. LPTX is outperformed by 75.89% of its industry peers.
With a Return On Equity value of -132.42%, LPTX is not doing good in the industry: 62.50% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -99.66%
ROE -132.42%
ROIC N/A
ROA(3y)-74.59%
ROA(5y)-148.47%
ROE(3y)-88.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LPTX Yearly ROA, ROE, ROICLPTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2K -2K

1.3 Margins

LPTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LPTX Yearly Profit, Operating, Gross MarginsLPTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -500 -1K -1.5K -2K -2.5K

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for LPTX has been increased compared to 1 year ago.
Compared to 5 years ago, LPTX has more shares outstanding
There is no outstanding debt for LPTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LPTX Yearly Shares OutstandingLPTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
LPTX Yearly Total Debt VS Total AssetsLPTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -11.67, we must say that LPTX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -11.67, LPTX is not doing good in the industry: 77.14% of the companies in the same industry are doing better.
There is no outstanding debt for LPTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.67
ROIC/WACCN/A
WACCN/A
LPTX Yearly LT Debt VS Equity VS FCFLPTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

LPTX has a Current Ratio of 3.97. This indicates that LPTX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.97, LPTX is in line with its industry, outperforming 45.36% of the companies in the same industry.
A Quick Ratio of 3.97 indicates that LPTX has no problem at all paying its short term obligations.
The Quick ratio of LPTX (3.97) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.97
Quick Ratio 3.97
LPTX Yearly Current Assets VS Current LiabilitesLPTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

LPTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 65.66%, which is quite impressive.
EPS 1Y (TTM)65.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 12.21% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y63.26%
EPS Next 2Y32.15%
EPS Next 3Y20.67%
EPS Next 5Y12.21%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LPTX Yearly Revenue VS EstimatesLPTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
LPTX Yearly EPS VS EstimatesLPTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

LPTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LPTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LPTX Price Earnings VS Forward Price EarningsLPTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LPTX Per share dataLPTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as LPTX's earnings are expected to grow with 20.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.15%
EPS Next 3Y20.67%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LPTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEAP THERAPEUTICS INC

NASDAQ:LPTX (2/28/2025, 8:00:00 PM)

Premarket: 0.4633 0 (0%)

0.4633

0 (-0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)03-17 2025-03-17/amc
Inst Owners52.3%
Inst Owner Change31.18%
Ins Owners0.25%
Ins Owner Change0%
Market Cap17.75M
Analysts77.78
Price Target2.17 (368.38%)
Short Float %10.12%
Short Ratio3.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.21%
Min EPS beat(2)-18.56%
Max EPS beat(2)10.13%
EPS beat(4)3
Avg EPS beat(4)6.03%
Min EPS beat(4)-18.56%
Max EPS beat(4)18%
EPS beat(8)6
Avg EPS beat(8)-21.4%
EPS beat(12)8
Avg EPS beat(12)-17.33%
EPS beat(16)9
Avg EPS beat(16)-14.74%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-78.37%
PT rev (3m)-81.32%
EPS NQ rev (1m)-0.44%
EPS NQ rev (3m)0.65%
EPS NY rev (1m)0%
EPS NY rev (3m)0.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.36
P/tB 0.36
EV/EBITDA N/A
EPS(TTM)-1.93
EYN/A
EPS(NY)-1.29
Fwd EYN/A
FCF(TTM)-1.44
FCFYN/A
OCF(TTM)-1.44
OCFYN/A
SpS0
BVpS1.28
TBVpS1.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -99.66%
ROE -132.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-74.59%
ROA(5y)-148.47%
ROE(3y)-88.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.97
Quick Ratio 3.97
Altman-Z -11.67
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.73%
EPS Next Y63.26%
EPS Next 2Y32.15%
EPS Next 3Y20.67%
EPS Next 5Y12.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-21.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-18.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.01%
OCF growth 3YN/A
OCF growth 5YN/A